Mindray has announced the introduction and global launch of two new high-sensitivity troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The additions enhance Mindray's diverse portfolio of cardiac biomarkers for diagnosing and managing cardiovascular diseases (CVDs), according to a written statement issued by the global medical devices and solutions provider. Image courtesy: Mindray
October 23, 2030 — Global medical devices and solutions provider Mindray has announced the introduction and global launch of two new high-sensitivity troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The additions enhance Mindray's diverse portfolio of cardiac biomarkers for diagnosing and managing cardiovascular diseases (CVDs), according to a written statement issued recently on the launch, which noted the new offerings are the result of Mindray's ongoing efforts in developing advanced chemiluminescence immunoassay products.
While CVDs are the leading cause of death worldwide, the company reinforced that early detection is key in saving lives. The statement further offered that guidelines recommend the use of cTnl and NT-proBNP as essential biomarkers for suspected Acute Coronary Syndrome (ACS) and heart failure. They enable early screening, risk stratification, rapid diagnosis, and therapeutic monitoring, aiding timely life-saving clinical decisions.
Mindray's hs-cTnI and NT-proBNP assays are the outcome of a fruitful collaboration between Mindray and HyTest, a prominent global provider of antibodies and antigens acquired by Mindray in 2021. The statement also reported that HyTest, renowned for their cardiac biomarker expertise, had their cardiac troponin complex material selected as the international troponin standard by AACC in 2004.
Mindray's announcement offered the following details: The hs-cTnI assay far surpasses the minimum requirements for hs-cTn by achieving a remarkable 93% detection rate between LoD and 99th URL and an imprecision CV below 5% at the 99th URL. This demonstrates the assay's exceptional sensitivity, precision, and reliability in detecting myocardial injury. Furthermore, a 0-2h diagnostic algorithm study conducted at the Hennepin Healthcare Research Institute further supports its effectiveness in accurately diagnosing and managing cardiac conditions within this crucial timeframe.
NT-proBNP is an established cardiac marker for heart failure and its management. Mindray's NT-proBNP assay demonstrates high precision with a CV of ≤5% and effectively minimizes interference from 55 common medications for heart diseases, making it a reliable tool for heart failure detection and management.
“Through integrating HyTest's pioneering antibodies and research on cardiac biomarkers with Mindray's advanced reagent technology and platform, we will deliver more reliable solutions that bring improved patient outcomes in the field of cardiovascular diseases and beyond,” said Mindray IVD Chief Scientific Officer, Dr. Jianwen He.
The company also reported that in catering to the diverse needs of its customers, it has integrated hs-cTnI, NT-proBNP, BNP, TnI, CK-MB, and MYO into its comprehensive cardiac total solution for clinical application and management, adding that the panel is designed for easy usability across all of Mindray’s immunoassay platforms.
More information: www.mindray.com
July 18, 2024 
